JP2024129122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024129122A5 JP2024129122A5 JP2024107963A JP2024107963A JP2024129122A5 JP 2024129122 A5 JP2024129122 A5 JP 2024129122A5 JP 2024107963 A JP2024107963 A JP 2024107963A JP 2024107963 A JP2024107963 A JP 2024107963A JP 2024129122 A5 JP2024129122 A5 JP 2024129122A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- less
- active agent
- suspension
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 239000013543 active substance Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 239000000725 suspension Substances 0.000 claims 8
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 claims 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 5
- 229960004502 levodopa Drugs 0.000 claims 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 4
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000002002 slurry Substances 0.000 claims 4
- 229960004205 carbidopa Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 239000000375 suspending agent Substances 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims 2
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LQQFFJFGLSKYIR-UHFFFAOYSA-N 3,4-dihydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C(O)=C1 LQQFFJFGLSKYIR-UHFFFAOYSA-N 0.000 claims 1
- IUUBODMNDCMSEU-UHFFFAOYSA-N 3-[6-amino-3-(3-hydroxypropyl)-2,4,5,9-tetrahydropurin-2-yl]propan-1-ol Chemical compound NC1=NC(CCCO)N(CCCO)C2N=CNC12 IUUBODMNDCMSEU-UHFFFAOYSA-N 0.000 claims 1
- 229940123973 Oxygen scavenger Drugs 0.000 claims 1
- 229910000831 Steel Inorganic materials 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- DZAUWHJDUNRCTF-UHFFFAOYSA-N dihydrocaffeic acid Natural products OC(=O)CCC1=CC=C(O)C(O)=C1 DZAUWHJDUNRCTF-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000001198 duodenum Anatomy 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000011261 inert gas Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000001630 jejunum Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004644 moclobemide Drugs 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 claims 1
- 229950002652 safinamide Drugs 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- 229960004603 tolcapone Drugs 0.000 claims 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105565P | 2015-01-20 | 2015-01-20 | |
| US62/105,565 | 2015-01-20 | ||
| US201562272922P | 2015-12-30 | 2015-12-30 | |
| US62/272,922 | 2015-12-30 | ||
| JP2020214665A JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2023022208A JP2023058678A (ja) | 2015-01-20 | 2023-02-16 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023022208A Division JP2023058678A (ja) | 2015-01-20 | 2023-02-16 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024129122A JP2024129122A (ja) | 2024-09-26 |
| JP2024129122A5 true JP2024129122A5 (https=) | 2025-02-06 |
Family
ID=55410198
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556790A Pending JP2018503686A (ja) | 2015-01-20 | 2016-01-20 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2020214665A Active JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2023022208A Ceased JP2023058678A (ja) | 2015-01-20 | 2023-02-16 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2024107963A Pending JP2024129122A (ja) | 2015-01-20 | 2024-07-04 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556790A Pending JP2018503686A (ja) | 2015-01-20 | 2016-01-20 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2020214665A Active JP7232235B2 (ja) | 2015-01-20 | 2020-12-24 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
| JP2023022208A Ceased JP2023058678A (ja) | 2015-01-20 | 2023-02-16 | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10117843B2 (https=) |
| EP (2) | EP3247330A1 (https=) |
| JP (4) | JP2018503686A (https=) |
| KR (1) | KR20170103967A (https=) |
| CN (2) | CN116036064A (https=) |
| AU (1) | AU2016209420B2 (https=) |
| BR (1) | BR112017015613B1 (https=) |
| CA (1) | CA2974203A1 (https=) |
| IL (1) | IL253487A0 (https=) |
| MA (1) | MA41377A (https=) |
| MX (1) | MX384262B (https=) |
| PH (1) | PH12017501304A1 (https=) |
| RU (1) | RU2017129375A (https=) |
| SG (1) | SG11201705964YA (https=) |
| TW (1) | TW201639556A (https=) |
| WO (1) | WO2016118556A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2743347C2 (ru) | 2014-10-21 | 2021-02-17 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| WO2018017850A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| CN113015531A (zh) | 2018-11-15 | 2021-06-22 | 艾伯维公司 | 用于皮下施用的药物调配物 |
| CN119510592A (zh) * | 2023-08-22 | 2025-02-25 | 上海汉都医药科技有限公司 | 一种含有卡比多巴的药物中肼含量的检测方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3132171A (en) | 1962-06-18 | 1964-05-05 | Strong Cobb Arner Inc | 3, 4-diphosphatophenyl-alanine and process for making same |
| US4618484A (en) | 1983-03-30 | 1986-10-21 | Yale University | Composition and method for treatment of melanomas |
| DE69016688T2 (de) | 1989-04-20 | 1995-10-05 | Zambon Spa | Dopamin-Medikament-Vorstufe. |
| IT1255471B (it) | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
| EP1596808A4 (en) | 2003-02-07 | 2007-04-04 | Yissum Res Dev Co | L-DOPA AMID DERIVATIVES AND THEIR USE |
| RU2484815C2 (ru) * | 2006-05-31 | 2013-06-20 | Зольвай Фармасьютиклз Гмбх | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| WO2010134074A1 (en) | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| WO2011056240A2 (en) | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| EP2640358B1 (en) * | 2010-11-15 | 2018-01-03 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| BR112013014304A2 (pt) | 2010-12-10 | 2016-07-19 | Synagile Corp | composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão |
| WO2012158527A2 (en) | 2011-05-13 | 2012-11-22 | Howmedica Osteonics | Organophosphorous & multivalent metal compound compositions & methods |
| WO2013033453A2 (en) * | 2011-08-31 | 2013-03-07 | Abbott Laboratories | Sealing arrangement for syringe |
| PT2968218T (pt) | 2013-03-13 | 2021-09-24 | Neuroderm Ltd | Combinação para tratamento da doença de parkinson |
| KR102457026B1 (ko) * | 2013-11-05 | 2022-10-21 | 신애질 코포레이션 | 입을 통한 연속적 약물 전달 |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
-
2016
- 2016-01-19 MA MA041377A patent/MA41377A/fr unknown
- 2016-01-20 EP EP16706041.7A patent/EP3247330A1/en not_active Withdrawn
- 2016-01-20 KR KR1020177022953A patent/KR20170103967A/ko not_active Withdrawn
- 2016-01-20 JP JP2017556790A patent/JP2018503686A/ja active Pending
- 2016-01-20 RU RU2017129375A patent/RU2017129375A/ru not_active Application Discontinuation
- 2016-01-20 MX MX2017009325A patent/MX384262B/es unknown
- 2016-01-20 US US15/001,392 patent/US10117843B2/en active Active
- 2016-01-20 SG SG11201705964YA patent/SG11201705964YA/en unknown
- 2016-01-20 CA CA2974203A patent/CA2974203A1/en not_active Abandoned
- 2016-01-20 TW TW105101753A patent/TW201639556A/zh unknown
- 2016-01-20 EP EP24194552.6A patent/EP4470611A3/en not_active Withdrawn
- 2016-01-20 CN CN202310053820.6A patent/CN116036064A/zh active Pending
- 2016-01-20 CN CN201680016049.3A patent/CN107427463A/zh active Pending
- 2016-01-20 WO PCT/US2016/014005 patent/WO2016118556A1/en not_active Ceased
- 2016-01-20 BR BR112017015613-0A patent/BR112017015613B1/pt not_active IP Right Cessation
- 2016-01-20 AU AU2016209420A patent/AU2016209420B2/en active Active
-
2017
- 2017-07-14 IL IL253487A patent/IL253487A0/en unknown
- 2017-07-18 PH PH12017501304A patent/PH12017501304A1/en unknown
-
2018
- 2018-10-16 US US16/161,940 patent/US20190142777A1/en not_active Abandoned
-
2020
- 2020-03-18 US US16/822,892 patent/US20210046029A1/en not_active Abandoned
- 2020-12-24 JP JP2020214665A patent/JP7232235B2/ja active Active
-
2023
- 2023-02-16 JP JP2023022208A patent/JP2023058678A/ja not_active Ceased
-
2024
- 2024-07-04 JP JP2024107963A patent/JP2024129122A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024129122A5 (https=) | ||
| JP6889231B2 (ja) | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 | |
| JP2572768B2 (ja) | レボドパメチルエステルを有効成分とするパ−キンソン病治療剤 | |
| JP6387171B2 (ja) | Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与 | |
| JP2023058678A5 (https=) | ||
| CN102438587B (zh) | 用于多巴脱羧酶抑制剂连续施用的组合物 | |
| JP7232235B2 (ja) | レボドパおよびカルビドパ経腸用ゲル剤ならびに使用方法 | |
| JP2022166217A (ja) | レボドパ及びカルビドパ腸管ゲル、並びに使用方法 | |
| JP2022166217A5 (https=) | ||
| WO2019240697A2 (en) | Pharmaceutical compositions for parenteral administration comprising lacosamide | |
| Haefeli | Drug-drug interactions with levodopa modulating treatment responses in Parkinson's disease | |
| JP2025113084A (ja) | 皮下投与用腸疾患粘膜治癒材 |